Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GHK-Cu regulatory status

Current status of GHK-Cu in the United States: Nomination withdrawn. In sport: WADA status unclear. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of GHK-Cu?

Regulatory: Nomination withdrawnWADA: WADA status unclearVerified: Verified Sep 30, 2026
FDA and compounding
GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it can be sold without FDA premarket approval, as long as the product makes no drug claims. As a drug it is not FDA approved. For compounding, FDA treats it by route. GHK-Cu for non-injectable routes is in 503A Category 1 (under evaluation). Under FDA's interim policy, FDA does not intend to act against a 503A pharmacy or physician that compounds it for an identified patient on a prescription, if the ingredient comes from a registered manufacturer with a valid certificate of analysis and all other 503A conditions are met. GHK-Cu for injectable routes was in Category 2 and is now on FDA's list of withdrawn nominations. That list is outside any category and outside the interim policy, so as of the last verification date a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk. FDA has said it intends to consult the Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. FDA has also warned that 'research use only' labels do not make a product lawful when it is intended for use in people.
WADA
WADA status unclear
Access path
  1. Topical cosmetic products containing GHK-Cu are sold over the counter without a prescription, as long as they make only cosmetic claims.
  2. No lawful compounded path for injectable GHK-Cu today: FDA lists it as a withdrawn 503A nomination, so it is off Category 2 but not on the 503A bulks list, and a 503A pharmacy has no federal basis to compound it from bulk.
  3. Not available as an FDA approved drug; injectable products labeled research use only are unapproved drugs when sold for human use.

Full GHK-Cu page: evidence, dosing in the literature, and sources

How has the status of GHK-Cu changed over time?

  1. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for GHK-Cu and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  5. [5]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026

From the blog